New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
06:11 EDTCELGCelgene well positioned into May 15 Markman hearing, says Citigroup
Citigroup believes Celgene is well positioned into the Markman hearing against Natco on May 15. The firm thinks Celgene's arguments over the Revlimid patents are more compelling than Natco's. Citi views Celgene shares as cheap and keeps a Buy rating on the name with a $199 price target.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
11:00 EDTCELGCelgene to hold an analyst and investor event
Subscribe for More Information
07:06 EDTCELGAmerican Society of Clinical Oncology to hold annual meeting
Subscribe for More Information
May 26, 2015
20:50 EDTCELGBernstein to hold a conference
Subscribe for More Information
07:39 EDTCELGCelgene management to meet with SunTrust
Group dinner to be held in New York on May 27 hosted by SunTrust.
May 21, 2015
08:08 EDTCELGAgios Pharmaceuticals to present data at 20th Congress of EHA
Subscribe for More Information
May 19, 2015
08:17 EDTCELGCelgene says patients experienced clinical remission in Phase II GED-0301 trial
Subscribe for More Information
May 18, 2015
08:44 EDTCELGCelgene data positive, says SunTrust
SunTrust believes that data presented for Celgene's GED-0301 in Crohn's indicated that the drug is effective irrespective of baseline disease severity and CRP levels.Consequently, the firm thinks the data addressed questions raised in an NEJM editorial about the drug. It keeps a $141 price target and Buy rating on the shares.
07:31 EDTCELGCelgene, Acceleron granted fast track designations for luspatercept
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use